|
|
Profile
|
Delegates :
Tomohiro Yamaguchi , M.D., Ph.D. |

|
Incorporated :
May 27 , 2019 |
Paid in Capital :
5 Million yen |
Employees :
人 |
Address :
S-1 Building, 3-5-2 Ueno, Taito-ku TOKYO
〒110-0005
|
TEL/FAX :
+81-90-1215-3737 / |
URL:
https://www.oxycarrier.com/ |
Attachment :
|
Mission/Background :
Oxycarrier Inc. is a biotechnology startup dedicated to solving the critical shortage of transfusion blood in veterinary medicine through the development of liposome-encapsulated artificial red blood cells. The company commercializes technologies originally developed at Waseda University and further advanced through collaborative research with Nara Medical University. Oxycarrier aims to provide safe, long-storable, and blood type-independent oxygen carriers for animals, enabling timely treatment in emergency situations and transforming veterinary transfusion medicine worldwide. |
|
Technology & Business
|
Oxycarrier develops artificial oxygen carriers based on liposome-encapsulated hemoglobin technology. The proprietary artificial red blood cells offer excellent oxygen transport capability while providing long-term storage stability, low infection risk, and compatibility regardless of blood type or animal species. The company is engaged in the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, research reagents, and technologies related to artificial red blood cells, while also conducting collaborative research and contract development projects.
|
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
Veterinary Liposome-based Artificial Red Blood Cells
|
Preclinical
|
Artificial oxygen carrier for veterinary transfusion medicine
|
Regulatory approval and clinical development
|
Artificial Red Blood Cell Manufacturing Platform
|
Discovery
|
Proprietary manufacturing technology for artificial RBCs
|
Process optimization and scale-up
|
Collaborative Research Program
|
Launched
|
Joint research on artificial blood applications
|
Expansion of research partnerships
|
Veterinary Diagnostic R&D Services
|
Launched
|
Contract research and development support
|
Customer acquisition and project growth
|
|
|
|
|
|
Highlights
|
In 2024, Oxycarrier acquired key patents related to the manufacturing of liposome-based artificial red blood cells from Waseda University. The company was also certified as a Nara Medical University Venture and has been selected for the FASTAR acceleration program operated by the Organization for Small & Medium Enterprises and Regional Innovation, Japan (SMRJ).
|
|
Hot news
|
Oxycarrier continues to advance the commercialization of veterinary artificial red blood cells. Following the acquisition of core intellectual property and recognition as a Nara Medical University venture, the company is accelerating product development toward practical application in veterinary medicine.
|
|
Alliance strategy
|
Oxycarrier is seeking collaborative opportunities with veterinary hospitals, universities, research institutes, and pharmaceutical companies to accelerate the development and commercialization of artificial red blood cells for veterinary use. The company is also interested in partnerships for manufacturing, distribution, global market expansion, and technology development.
|
|
|